COPENHAGEN, April 28, 2026 — Denmark’s Danish Competition Appeals Tribunal has published a non-confidential version of its decision confirming that Coloplast A/S abused its dominant position in the supply of stoma care products.
The ruling, issued in March and now made public after confidentiality issues were resolved, upholds a 2025 decision by the Danish Competition Council finding that the company engaged in a margin squeeze.
Margin squeeze strategy
According to the authorities, Coloplast’s pricing practices squeezed the margins of competing wholesalers seeking to supply the company’s stoma care products to municipalities.
The conduct effectively discouraged wholesalers from competing to distribute the products, thereby limiting competition in the supply chain for municipal procurement.
The competition authority also found that the company’s behaviour contributed to a significant decline in parallel imports of stoma care products.
Order to cease conduct
As part of its original decision, the Danish Competition Council ordered Coloplast to cease the abusive pricing practices and refrain from similar conduct in the future.
The Appeals Tribunal’s ruling confirms the authority’s findings and legal assessment.
Publication after confidentiality review
The tribunal’s decision has only now been published after the resolution of confidentiality issues concerning the information contained in the ruling.
The case concerns the market for stoma care medical devices supplied to Danish municipalities, where Coloplast holds a strong position as a manufacturer.
